HTR1B

5-hydroxytryptamine receptor 1B · P28222 · HTR1B on Sugi Atlas →

135,273 patent compounds predicted against HTR1B, 87,671 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Naratriptan (SCHEMBL68753)	1.00	13/20
Naratriptan (SCHEMBL41527)	0.98	13/20
Naratriptan (SCHEMBL41528)	0.96	13/20
SCHEMBL220724	0.73	12/20
SCHEMBL74962	0.70	12/20
SCHEMBL97164	0.68	12/20
SCHEMBL68267	0.67	12/20
Dapoxetine (SCHEMBL34479)	0.57	12/20
Dapoxetine (SCHEMBL119037)	0.56	12/20
Oxymetazoline (SCHEMBL24301)	1.00	11/20
Zolmitriptan (SCHEMBL33336)	1.00	11/20
Zolmitriptan (SCHEMBL40595)	1.00	11/20
Oxymetazoline (SCHEMBL41247)	0.97	11/20
Xylometazoline (SCHEMBL34087)	1.00	10/20
Xylometazoline (SCHEMBL41837)	0.97	10/20
SCHEMBL45343	0.61	10/20
SCHEMBL189974	0.48	10/20
SCHEMBL189975	0.41	10/20
Eletriptan (SCHEMBL26719)	1.00	9/20
SCHEMBL194699	0.76	9/20

Clinical trials — most relevant to HTR1B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder	PHASE4	COMPLETED
Serotonin Transporter Genetic Variation and Amygdala Responses to Antidepressant Medications in Major Depression	PHASE4	COMPLETED
An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and ATS Dependence	PHASE3	UNKNOWN
Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression	PHASE1/PHASE2	RECRUITING
Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)	PHASE2	NOT_YET_RECRUITING
5HT2CR Balance in Brain Connectivity in Cocaine Dependence	PHASE1/PHASE2	COMPLETED
Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder	PHASE2	RECRUITING
Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of Concept	PHASE2	COMPLETED
Clinical and Mechanistic Effects of Psilocybin in Alcohol Addicted Patients	PHASE2	COMPLETED
Effects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects	PHASE1	COMPLETED
The Neurobiological Effect of 5-HT2AR Modulation	PHASE1	RECRUITING
Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)	PHASE1	RECRUITING
Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers	PHASE1	COMPLETED
Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects	PHASE1	COMPLETED
Precision Functional Brain Mapping in Psilocybin	EARLY_PHASE1	COMPLETED
SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis	EARLY_PHASE1	UNKNOWN
Epigenetic and Neurochemical Correlates of Bipolar Disorder	nan	NOT_YET_RECRUITING
Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors	nan	COMPLETED
The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers	nan	COMPLETED
PET Whole Body Distribution Studies Using [11C]CUMI	nan	COMPLETED
Correlation Between Peri-implantitis and Assumptions of Medications	nan	COMPLETED
The Pill Project - Oral Contraceptive and Serotonergic Brain Signaling	nan	UNKNOWN
Hormonal Causes of Menstrual-Related Mood Disorders	nan	COMPLETED
Investigating the Neuropsychological Effects of 5-HT2a Antagonism	nan	RECRUITING
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
Effects of Lurasidone on Left Ventricle Systolic Functions	nan	NOT_YET_RECRUITING
Trazodone and the Risk of Serious Adverse Events	nan	COMPLETED
Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression	nan	COMPLETED
Microdosing LSD in Women With Premenstrual Disorders	nan	NOT_YET_RECRUITING
Examination of Brain Serotonin Receptors in Patients With Mood Disorders	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a HTR1B binder may also engage these)

Protein	Name	Similarity
Q9N2B7	—	1.000	Q9N2B7 →
Q6XXX8	—	1.000	Q6XXX8 →
P79250	—	1.000	P79250 →
P79748	—	1.000	P79748 →
P60020	—	1.000	P60020 →
Q588Y6	—	1.000	Q588Y6 →
P56496	—	1.000	P56496 →
P28334	—	1.000	P28334 →
Q0EAB5	—	1.000	Q0EAB5 →
Q6XXX9	—	1.000	Q6XXX9 →
P28564	—	0.999	P28564 →
P35404	—	0.999	P35404 →
O08892	—	0.999	O08892 →
Q6XXY0	—	0.998	Q6XXY0 →
P49144	—	0.998	P49144 →
P52703	—	0.997	P52703 →
P11614	—	0.997	P11614 →
O42385	—	0.997	O42385 →
P46636	—	0.997	P46636 →
DRD3	D(3) dopamine receptor	0.996	landscape →
P49145	—	0.996	P49145 →
Q0EAB6	—	0.994	Q0EAB6 →
P19327	—	0.994	P19327 →
Q9N2D9	—	0.994	Q9N2D9 →
Q91175	—	0.994	Q91175 →
O42384	—	0.993	O42384 →
P42288	—	0.993	P42288 →
Q61224	—	0.993	Q61224 →
HTR1E	5-hydroxytryptamine receptor 1E	0.993	landscape →
Q95136	—	0.993	Q95136 →